



EUROPEAN ASSOCIATION OF
PHARMA BIOTECHNOLOGY

Science to Market 2013

-Programme-

Cologne Germany - March 5 – 6, 2013



PERSONALIZED MEDICINE

Trends in 2013

Conference and Marketplace for Life Science Technologies from Academia

European Association of Pharma Biotechnology (EAPB)

in cooperation with



Kindly supported by



Industrie- und Handelskammer
zu Köln

Platinum Sponsor



Bayer HealthCare

Silver Sponsor



Confirmed Technology-
Transfer Partners



DEUTSCHES
KREBSFORSCHUNGSZENTRUM
IN DER HELMHOLTZ-GEMEINSCHAFT



Innovations-Management
Rheinland-Pfalz



ERFINDUNGEN BEWEGEN
Erfinderzentrum
Norddeutschland GmbH



MEDIZINISCHE
UNIVERSITÄT
WIEN



ESA Patentverwertungsagentur
ESA Patentverwertungsagentur Sachsen-Anhalt
Partner für Innovationen



Universität des Saarlandes
Wissens- und
Technologietransfer GmbH
PatentVerwertungsAgentur PVA



Patent- und Verwertungsagentur für die wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH



Aus Ideen Werte schaffen



rubitec



Gesellschaft für Innovation und Technologie der Ruhr-Universität Bochum

TransMIT - Markt für Ideen und Innovationen

Cologne Chamber of Commerce (IHK Köln)
Unter Sachsenhausen 10-26, 50667 Cologne, Germany

Tuesday, March 5, 2013

12:30 – 13:00 **Registration**

13:00 – 13:15 **Welcome, Introduction & Opening remarks**

Wieland W. Wolf, President of EAPB, and Jürgen Walkenhorst, PROvendis GmbH

13:15 – 14:00 **Keynote “Personalized Medicine – current status and future practice”**

Thomas Gottwald, Ovesco Endoscopy AG

Trends in Preclinical Development

14:00 – 14:35 **“Bone Sialoprotein II as target in the treatment of breast cancer skeletal metastasis”**

Martin Berger, German Cancer Research Center (DKFZ)

14:35 – 15:10 **“Blood-born miRNome of human diseases”**

Eckart Meese, University of Saarland

Coffee Break (30 min)

15:40 – 16:15 **“Next generation sequencing technologies: the impact on personalized medicine”**

Kerstin Stangier, GATC Biotech AG

16:15 – 17:00 **Panel Discussion**

Oral poster presentations

17:00 – 18:30 **Session 1: Novel therapeutics, vaccines and diagnostics**

1a) Novel therapeutics

1b) Novel vaccines

1c) Novel diagnostics

Session 2: Novel technologies

2a) Novel up- and downstream developments

2b) Novel biopharmaceuticals drug formats and pharmaceutical developments

2c) Novel analytical tools

18:30 – 18:45 **Closing Remarks for day 1**

19:00

Come together/Social Event

Cologne Chamber of Commerce (IHK Köln)
Unter Sachsenhausen 10-26, 50667 Cologne, Germany

Wednesday, March 6, 2013

Biomarkers for Decision making

9:00 – 9:35 **“From research to clinic: application of sophisticated exploratory biomarkers in clinical studies”**

Andrea Groenewegen, Novartis Pharma AG

9:35 – 10:10 **“Fit for purpose – Biomarkers: Opportunities and Challenges”**

Marion Rudolph, Bayer Pharma AG

10:10 – 10:45 **“Application of biomarkers in medical diagnostics”**

Stephan Wnendt, MLM Medical Labs GmbH

10:45 – 11:30 **Panel Discussion**

Coffee Break (30 min)

Oral Poster Presentations and Partnering-Session

12:00 – 13:00 **Elevator Pitches of Companies and Technology offers**

13:00 – 14:00 **Lunch Break (Finger Food) at poster boards**

Entering the Market: Technology Transfer, Regulation and Reimbursement of personalized Medicine

14:00 – 14:35 **“A technology transfer organisation's perspective on personalised medicine”**

Jürgen Walkenhorst, PROvendis GmbH

14:35 – 15:10 **“Regulatory challenges of personalized medicine and companion diagnostic”**

Jörg Engelbergs, Paul-Ehrlich-Institute (PEI)

15:10 – 15:45 **“Reimbursement and personalized medicine from the European perspective”**

Alexander Natz, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

15:45 – 16:20 **Panel Discussion**

16:20 – 16:30 **Closing Remarks and end of the conference**